We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reckitt Benckiser Group Plc | LSE:RB. | London | Ordinary Share | GB00B24CGK77 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6,498.00 | 6,502.00 | 6,506.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
By Olga Cotaga
LONDON--Reckitt Benckiser Group PLC (RB.LN) reported Friday a first-quarter revenue of 2.64 billion pounds ($3.31 billion), 15% up considering the foreign exchange rates.
Excluding the impact of changes in exchange rates, like-for-like revenue stayed unchanged, but the company backed its full-year guidance of 3% growth.
Revenue in the first three months of 2017 was helped by a good performance from the health unit, which offset the headwinds in the Scholl and Amopé unit.
The acquisition of Mead Johnson is on track and should be completed by the end of the third quarter, the company said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
April 21, 2017 02:28 ET (06:28 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Reckitt Benckiser Chart |
1 Month Reckitt Benckiser Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
